Industry News
Biotechnology Industry News
Evotec has escalated its already…
Evotec has escalated its already substantial reorganization, plotting an additional round of layoffs and site closures that will impact one-sixth of the German drug discoverer’s workforce.
With a fresh leadership team…
With a fresh leadership team settling in, CNS Pharmaceuticals is wiping its pipeline clean as it hunts for a new lead asset in a strategic pivot.
French biotech Enodia Therapeutics…
French biotech Enodia Therapeutics is paying $1 million upfront in a back-loaded deal for Kezar Life Sciences’ preclinical protein degradation program.
Salspera has set out plans for a…
Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy.
Less than a week after Roche…
Less than a week after Roche pledged a hefty investment in the South Korean biopharma industry, Eli Lilly is following suit with a $500 million, five-year pact of its own.
Molecular glue-focused biotech f5…
Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years, according to an announcement from the company’s CEO on LinkedIn.
The FDA has resumed review of…
The FDA has resumed review of Capricor Therapeutics’ previously rejected Duchenne muscular dystrophy cell therapy following the biotech’s submission of more clinical data.
As tensions around the FDA…
As tensions around the FDA continue to escalate, a Republican U.S. senator has announced an investigation into recent approval rejections for rare disease candidates, according to Bloomberg News.
Voyager Therapeutics has hit pause…
Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset.
Ascletis Pharma has posted phase 2…
Ascletis Pharma has posted phase 2 data on its ultra-long-acting GLP-1 receptor analog, generating early evidence that the formulation may support quarterly dosing as a maintenance therapy.
Kalaris Therapeutics has paused a…
Kalaris Therapeutics has paused a phase 1 study of its next-gen eye drug while it attempts to finally resolve cases of eye inflammation.
BioNTech’s CEO and his fellow…
BioNTech’s CEO and his fellow co-founder will depart the mRNA powerhouse by the end of the year to helm a new company focused on “next generation mRNA innovations.”
Vertex reported a phase 3 win for…
Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval in November.
Bristol Myers Squibb’s…
Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival among multiple myeloma patients.
Xenon Pharmaceuticals’…
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients.
Shanghai-based Tenacia…
Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move for a Rapport Therapeutics asset focused on focal onset seizures and primary generalized tonic-clonic seizures, securing rights to develop and commercialize the candidate in China.
AbbVie has unveiled the first data…
AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin analog demonstrating weight loss of close to 10% after 12 weeks in certain patients.
Pfizer is ramping up plans for…
Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs.
Regeneron’s Chinese partner…
Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.
A phase 3 trial of Roche’s…
A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug candidate that hit the mark in adjuvant and second-line settings.